During the 4-week run-in phase adult patients will receive budesonide 800 mg and formoterol 24 mg. If a patient complies with all inclusion and exclusion criteria and has been receiving the according-to-age run-in proposed doses during the last month, the patient may continue to the stable-steroid phase.